Form 4: United Therapeutics COO Exercises and Sells Shares Under 10b5-1 Plan

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares on December 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock on December 2, 2024.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on August 7, 2024.
• The transactions involved the exercise of 10,000 stock options at prices of $102.11 and $111, and the subsequent sale of 10,000 shares at various prices ranging from $367.66 to $374.48.
• The shares were held in a trust, with some shares beneficially owned by the reporting person and others by family members.
• The reporting person has undertaken to provide full information regarding the number of shares and prices at which the transactions were effected upon request.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction by an executive under a pre-planned trading plan. While the sale of shares could be perceived negatively, the use of a 10b5-1 plan mitigates this concern. The sentiment is neutral to slightly positive due to the transparency of the transaction.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which is a common practice for corporate insiders to avoid accusations of insider trading.
• The reporting person has undertaken to provide full information regarding the number of shares and prices at which the transactions were effected upon request, indicating transparency.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react negatively to the sale of shares by a high-ranking executive, even if it is part of a pre-planned strategy.
• There is a risk of misinterpretation of the transactions if the details are not fully understood by investors.

Industry Context

This type of transaction is common for executives at publicly traded companies, especially when they have stock options that are vesting. The use of a 10b5-1 plan is a standard practice to avoid any appearance of insider trading.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology and pharmaceutical sectors, including companies like Amgen, Gilead Sciences, and Biogen.
• These plans allow executives to sell shares at predetermined times and prices, avoiding accusations of insider trading.
• The price range of the share sales is within the typical trading range for United Therapeutics stock, and the volume of shares sold is not unusual for an executive exercising options.

Stakeholder Impact

• Shareholders may react to the news of the executive's share sales, although the pre-planned nature of the transactions should mitigate any negative impact.
• Employees may be interested in the executive's transactions, but the use of a 10b5-1 plan should reassure them that the transactions are not based on inside information.

Key Dates

Keywords

insider trading, stock options, Rule 10b5-1, share sale, executive, United Therapeutics, UTHR, beneficial ownership, trust